{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:39:43Z","timestamp":1779244783889,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,5,20]],"date-time":"2015-05-20T00:00:00Z","timestamp":1432080000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014118","name":"Savient Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014118","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s00296-015-3284-3","type":"journal-article","created":{"date-parts":[[2015,5,19]],"date-time":"2015-05-19T08:22:49Z","timestamp":1432023769000},"page":"1799-1807","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Patient and clinical characteristics associated with gout flares in an integrated healthcare system"],"prefix":"10.1007","volume":"35","author":[{"given":"Nazia","family":"Rashid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald D.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengyi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"River","family":"Koblick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. Craig","family":"Cheetham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,20]]},"reference":[{"key":"3284_CR1","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/pgmj.2004.030692","volume":"81","author":"E Suresh","year":"2005","unstructured":"Suresh E (2005) Diagnosis and management of gout: a rational approach. Postgrad Med J 81:572\u2013579","journal-title":"Postgrad Med J"},{"key":"3284_CR2","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2165\/00003495-200666120-00002","volume":"66","author":"GG Teng","year":"2006","unstructured":"Teng GG, Nair R, Saag KG (2006) Pathophysiology, clinical presentation and treatment of gout. Drugs 66:1547\u20131563","journal-title":"Drugs"},{"issue":"3","key":"3284_CR3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","volume":"51","author":"A Shoji","year":"2004","unstructured":"Shoji A, Yamanaka H et al (2004) A retrospective study of the relationship between serum urate levels and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Care Res 51(3):321\u2013325","journal-title":"Arthritis Care Res"},{"key":"3284_CR4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/RHU.0b013e3181945d2c","volume":"15","author":"R Halpern","year":"2009","unstructured":"Halpern R, Fuldeore MJ, Mody RR, Patel PA, Mikuls TR (2009) The effect of serum urate on gout flares and their associated costs. An administrative claims analysis. J Clin Rheumatol 15:3\u20137","journal-title":"J Clin Rheumatol"},{"key":"3284_CR5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/01.rhu.0000209882.50228.9f","volume":"12","author":"CA Sarawate","year":"2006","unstructured":"Sarawate CA, Patel PA, Schumacher HR et al (2006) Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 12:61\u201365","journal-title":"J Clin Rheumatol"},{"key":"3284_CR6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1477-7525-10-117","volume":"10","author":"P Khanna","year":"2012","unstructured":"Khanna P, Nuki G, Bardin T, Tausche A, Forsythe A, Goren A, Veietri J, Khanna D (2012) Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: results from a cross-sectional survey. Health Qual Life Outcomes 10:117","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"3284_CR7","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/art.22232","volume":"55","author":"F Perez-Ruiz","year":"2006","unstructured":"Perez-Ruiz F, Atxotegi J, Hernando I et al (2006) Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long term urate lowering therapy: a prospective study. Arthritis Rheum 55(5):786\u2013790","journal-title":"Arthritis Rheum"},{"issue":"3","key":"3284_CR8","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0002-9343(87)90441-4","volume":"82","author":"EW Campion","year":"1987","unstructured":"Campion EW et al (1987) Asymptomatic hyperuricemia: risks and consequences in the normative aging study. Am L Med 82(3):421\u2013426","journal-title":"Am L Med"},{"key":"3284_CR9","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Khanna P, Fitzgerald JD, Singh MK, Bae S, Neogi T et al (2012) American College of Rheumatology guidelines for management of gout. Part 2: therapy and anti-inflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 64:1447\u20131461","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"3284_CR10","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/art.33483","volume":"64","author":"AL Gaffo","year":"2012","unstructured":"Gaffo AL, Schumacher HR, Saag KG, Taylor WJ, Dinnella J, Outman R et al (2012) Developing a provisional definition of flare in patients with established gout. Arthritis Rheum 64(5):1508\u20131517","journal-title":"Arthritis Rheum"},{"issue":"1","key":"3284_CR11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3111\/13696998.2010.540874","volume":"14","author":"N Edwards","year":"2011","unstructured":"Edwards N, Sundy J, Forsythe A et al (2011) Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. J Med Econ 14(1):10\u201315","journal-title":"J Med Econ"},{"key":"3284_CR12","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/ard.2007.081604","volume":"67","author":"J Singh","year":"2008","unstructured":"Singh J, Strand V (2008) Gout is associated with more comorbidities, poorer health related quality of life and higher healthcare utilization in US veterans. Ann Rheum Dis 67:1310\u20131316","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3284_CR13","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1089\/pop.2012.0057","volume":"16","author":"W Lynch","year":"2013","unstructured":"Lynch W, Chan W, Kleinman N, et al (2013) Economic burden of gouty arthritis attacks for employees with frequent and infrequent attacks. Popul Health Manag 16(2):138\u2013145","journal-title":"Popul Health Manag"},{"issue":"6","key":"3284_CR14","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1097\/MJT.0b013e31820543c5","volume":"19","author":"EQ Wu","year":"2012","unstructured":"Wu EQ, Forsythe A, Gu\u00e9rin A, Yu AP, Latremouille-Viau D, Tsaneva M (2012) Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy. Am J Ther 19(6):e157\u2013e166","journal-title":"Am J Ther"},{"key":"3284_CR15","first-page":"5","volume":"36","author":"EQ Wu","year":"2009","unstructured":"Wu EQ, Patel P, Mody R et al (2009) Frequency, risk, and cost of gout related episodes among the elderly: does serum uric acid level matter? J Rheumatol 36:5","journal-title":"J Rheumatol"},{"issue":"2","key":"3284_CR16","first-page":"e46","volume":"5","author":"C Le","year":"2013","unstructured":"Le C, Martin B, Cummins D et al (2013) Ambulatory resource utilization and cost for gout in United States. Am J Pharm Benefits 5(2):e46\u2013e54","journal-title":"Am J Pharm Benefits"},{"issue":"11","key":"3284_CR17","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1093\/rheumatology\/kes183","volume":"51","author":"J Saseen","year":"2012","unstructured":"Saseen J, Agashivala N, Allen R, et al (2012) Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks. Rheumatology 51(11):2004\u20132012. doi: 10.1093\/rheumatology\/kes183","journal-title":"Rheumatology"},{"issue":"4","key":"3284_CR18","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1185\/03007995.2011.552570","volume":"27","author":"B Pandya","year":"2011","unstructured":"Pandya B, Riedel A, Swindle J, Becker L et al (2011) Relationship between physician specialty and allopurinol prescribing patterns: a study of patients with gout in managed care settings. Curr Med Res Opin 27(4):737\u2013744","journal-title":"Curr Med Res Opin"},{"key":"3284_CR19","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/art.24166","volume":"61","author":"WJ Taylor","year":"2009","unstructured":"Taylor WJ, Shewchuk R, Saag KG, Shumacher HR, Singh JA, Grainger R et al (2009) Toward a valid definition of gout flare: results of consensus exercises using Delphi methodology and cognitive mapping. Arthritis Rheum 61:535\u2013543","journal-title":"Arthritis Rheum"},{"issue":"11","key":"3284_CR20","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/acr.22324","volume":"66","author":"C Zheng","year":"2014","unstructured":"Zheng C, Rashid N, Wu Y, Koblick R et al (2014) Using natural language processing and machine learning to identify gout flares from electronic clinical notes. Arthritis Care Res J 66(11):1740\u20131748","journal-title":"Arthritis Care Res J"},{"issue":"3","key":"3284_CR21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7812\/TPP\/12-031","volume":"16","author":"C Koebnick","year":"2012","unstructured":"Koebnick C, Langer-Gould AM, Gould MK, Chao CR, Iyer RL, Smith N, Chen W, Jacobsen SJ (2012) Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. Perm J Summer 16(3):37\u201341","journal-title":"Perm J Summer"},{"issue":"3","key":"3284_CR22","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1177\/1077558712466293","volume":"70","author":"SF Derose","year":"2013","unstructured":"Derose SF, Contreras R, Coleman KJ, Koebnick C, Jacobsen SJ (2013) Race and ethnicity data quality and imputation using U.S. census data in an integrated health system: the Kaiser Permanente Southern California experience. Med Care Res Rev 70(3):330\u2013345","journal-title":"Med Care Res Rev"},{"issue":"59","key":"3284_CR23","first-page":"1799","volume":"1999","author":"JR Pittman","year":"1810","unstructured":"Pittman JR, Bross MH (1810) Diagnosis and management of gout. Am Fam Physician 1999(59):1799\u20131806","journal-title":"Am Fam Physician"},{"key":"3284_CR24","first-page":"1575","volume":"31","author":"AA Reidel","year":"2004","unstructured":"Reidel AA, Nelson M, Jospeh-Ridge N et al (2004) Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol 31:1575\u20131581","journal-title":"J Rheumatol"},{"key":"3284_CR25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1471-2474-12-103","volume":"12","author":"P Primatesta","year":"2011","unstructured":"Primatesta P, Plana E, Rothenbacher D (2011) Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population. BMC Musculoskelet Disord 12:103","journal-title":"BMC Musculoskelet Disord"},{"key":"3284_CR26","unstructured":"Choi H The increasing burden of treatment failure gout (slides with transcript) (2007). http:\/\/www.medscape.org\/viewarticle\/559925 . Accessed 01 Dec 2014"},{"key":"3284_CR27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00002512-200724010-00002","volume":"24","author":"K Hoskison","year":"2007","unstructured":"Hoskison K, Wortman R (2007) Management of gout in older adults: barriers to optimal control. Drugs Aging 24:21\u201336","journal-title":"Drugs Aging"},{"issue":"8","key":"3284_CR28","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/ncprheum0556","volume":"3","author":"E Roddy","year":"2007","unstructured":"Roddy E, Zhang W, Doherty M (2007) The changing epidemiology of gout. Nat Clin Pract Rheumatol 3(8):443\u2013449","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"Suppl 1","key":"3284_CR29","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/ar1907","volume":"8","author":"K Saag","year":"2006","unstructured":"Saag K, Choi H (2006) Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther 8(Suppl 1):S2","journal-title":"Arthritis Res Ther"},{"issue":"14","key":"3284_CR30","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.clinthera.2011.01.008","volume":"32","author":"R Wortman","year":"2010","unstructured":"Wortman R, MacDonald P, Hunt B et al (2010) Effect of prophylaxis on gout flares after the initiation of urate lowering therapy: analysis of data from three phase III trials. Clin Ther 32(14):2386\u20132397","journal-title":"Clin Ther"},{"issue":"48","key":"3284_CR31","first-page":"ii2","volume":"2009","author":"M Doherty","year":"2009","unstructured":"Doherty M (2009) New insights into the epidemiology of gout. Rheumtology 2009(48):ii2\u2013ii8","journal-title":"Rheumtology"},{"key":"3284_CR32","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/rheumatology\/keq363","volume":"50","author":"D Rothenbacher","year":"2011","unstructured":"Rothenbacher D, Primatesta P et al (2011) Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology 50:973\u2013981","journal-title":"Rheumatology"},{"key":"3284_CR33","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","volume":"64","author":"L Stamp","year":"2012","unstructured":"Stamp L, Taylor WJ et al (2012) Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 64:2529\u20132536","journal-title":"Arthritis Rheum"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-015-3284-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-015-3284-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-015-3284-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T07:07:45Z","timestamp":1589526465000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-015-3284-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,20]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["3284"],"URL":"https:\/\/doi.org\/10.1007\/s00296-015-3284-3","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,20]]}}}